J&J Medical Connect
SPRAVATO®

(esketamine)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

Can SPRAVATO Cause Sedation, Dissociation, and Respiratory Depression?

Last Updated: 07/12/2024

summary

Here is a passage from the SPRAVATO MEDICATION GUIDE which may be helpful to address your question:

Can SPRAVATO cause sedation, dissociation, and respiratory depression?

  • SPRAVATO can cause serious side effects, including sedation, dissociation, and respiratory depression1:
    • SPRAVATO may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), and breathing problems (respiratory depression and respiratory arrest).
      • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
      • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO. Your healthcare provider will decide when you are ready to leave the healthcare setting.

SPRAVATO Risk Evaluation and Mitigation Strategy (REMS)

  • Because of the risks for sedation, dissociation, respiratory depression, abuse and misuse, SPRAVATO is only available through a restricted REMS program called the SPRAVATO REMS. SPRAVATO can only be administered at healthcare settings certified in the SPRAVATO Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO can only be administered at healthcare settings certified in the SPRAVATO REMS Program. Patients treated in outpatient healthcare settings (e.g. medical offices and clinics) must be enrolled in the program.1

What should I avoid while taking SPRAVATO?

  • Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO. Do not take part in these activities until the next day following a restful sleep.1

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest use in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT MEDICATION GUIDE for SPRAVATO.1

 

References

1 SPRAVATO (esketamine) nasal spray [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf.